Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Virus Evolution|December 8, 2022
Haplotype assignment of longitudinal viral deep sequencing data using covariation of variant frequenciesCristina Venturini, Juanita Pang, Asif U Tamuri, et al.
Virus Evolution|March 15, 2024
Genetic consequences of effective and suboptimal dosing with mutagenic drugs in a hamster model of SARS-CoV-2 infectionChristopher J R Illingworth, Jose A Guerra-Assuncao, Samuel Gregg, et al.
Clinical Pharmacology and Therapeutics|February 28, 2021
Systematic Review and Patient-Level Meta-Analysis of SARS-CoV-2 Viral Dynamics to Model Response to Antiviral TherapiesSilke Gastine, Juanita Pang, Florencia A T Boshier, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|May 11, 2020
Emergence of genomic diversity and recurrent mutations in SARS-CoV-2Lucy van Dorp, Mislav Acman, Damien Richard, et al.
Elife|December 31, 2020
Mixed cytomegalovirus genotypes in HIV-positive mothers show compartmentalization and distinct patterns of transmission to infantsJuanita Pang, Jennifer A Slyker, Sunando Roy, et al.
Genome Medicine|February 19, 2024
Detection of a historic reservoir of bedaquiline/clofazimine resistance-associated variants in Mycobacterium tuberculosisCamus Nimmo, Arturo Torres Ortiz, Cedric C S Tan, et al.
Journal of Medical Virology|August 20, 2021
Evolution of viral variants in remdesivir-treated and untreated SARS-CoV-2-infected pediatrics patientsFlorencia A T Boshier, Juanita Pang, Justin Penner, et al.
Clinical Immunology (Orlando, Fla.)|January 13, 2024
Favipiravir induces HuNoV viral mutagenesis and infectivity loss with clinical improvement in immunocompromised patientsAlexandra Y Kreins, Emma Roux, Juanita Pang, et al.
Ebiomedicine|September 27, 2021
The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection modelRana Abdelnabi, Caroline S Foo, Suzanne J F Kaptein, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2020
Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activitySuzanne J F Kaptein, Sofie Jacobs, Lana Langendries, et al.
Pageof 1